Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
  • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

• the present invention relates to pharmaceutical combination compositions in the field of pain treatment and control.
• neuropathic pain is pain that arises as a direct consequence of injury or disease affecting the somatosensory system.
• tramadol of formula I whose nomenclature is (1 ?,2R)-2- [(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexan-1-ol, is a synthetic codeine analog and analgesic of central action that possesses opioid agonist properties and activates spinal monoaminergic inhibition of pain; commonly used to treat acute neuropathic pain.
• Intravenous or intramuscular tramadol has generally been shown to be as potent as pethidine (meperidine) and one-fifth as potent as nalbuphine.
• Tramadol has demonstrated analgesic activity in various animal models, and in healthy volunteers with experimentally induced pain, oral tramadol has similar analgesic activity (Lee, Rhoda; McTavish, Donna; Sorkin, Eugene; Tramadol; A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Acute and Chronic Pain States, 1993).
• tramadol may include constipation, nausea, vomiting, stomach pain, dizziness, drowsiness, tiredness, and headache. Some side effects can be serious such as seizures, hives, blisters, difficulty swallowing, swelling of the eyes, face, throat, tongue, lips, hands, feet, ankles; and even changes in heart rhythm. Likewise, tramadol can be adjective especially after prolonged use. It is known that high doses of tramadol can cause increased side effects. Intentional and accidental overdoses of tramadol can cause respiratory arrest as well as acute liver failure, several fatal cases have been reported. In these cases, however, liver injury may have been caused by shock, hypoxia, or ischemia secondary to respiratory arrest.
• Liver injury attributed to tramadol overdose has also been associated with hyperammonemia, lactic acidosis, and hepatic steatosis, suggesting direct mitochondrial injury (Liver Tox Clinical and Research information of Drug-Induce Livered Injury, National Institutes of Health, December 05 , 2012).
• pregabalin also known as (3S)-3-(aminomethyl)-5-methylhexanoic acid, of formula II. It is a drug from the group of neuromodulators, with a better pharmacokinetic profile than its predecessors; it is also a GABA analog however it does not perform all of the GABAergic actions.
• Pregabalin has greater affinity than gabapentin, in addition to an analgesic effect due to its ability to bind to the alpha-2-delta protein subunit of voltage-gated calcium channels in the Central Nervous System (González Escalada, RL; Pregabalin in the treatment of peripheral neuropathic pain, Journal of the Spanish Society for pain, 2005).
• Pregabalin can cause side effects such as tiredness, dizziness, headache, dry mouth, nausea, vomiting, constipation, bloating, speech problems, anxiety, loss of balance, muscle spasms, weakness, among others. Some of these effects can also be serious, such as blurred or double vision, hives, blisters, swelling of the face, swelling of the arms, hands, and/or feet, shortness of breath, muscle pain, and chest pain.
• Adverse effects caused by high doses of pregabalin include dizziness, drowsiness, peripheral edema, dry mouth, headache, confusion, depression, and visual disturbances.
• compositions for treating pain include a pharmaceutically acceptable analgesic and a GABAergic agent, such as gamma vinyl GABA, effective to reduce or inhibit the side effect of the analgesic's adjective load. Said document does not indicate or describe a synergistic effect of the combination of an analgesic with a GABA agent.
• patent number US2013189354 describes the composition in gelatin capsules containing tramadol, pregabalin and dextromethorphan, in low concentrations; however, this composition does not describe or indicate a synergy of the compounds.
• publication of patent application US2015313892 describes the combination of tramadol with gabapentin or pregabalin, the latter in concentrations between 15 and 30 mg. Although this combination is described as synergistic, evidence for such synergy is not presented.
• Mexican patent application MX2017016720 describes the combination of an analog of y-aminobutyric acid (Gaba) and an opioid-type analgesic, where the first is pregabalin and the second is tramadol.
• Gaba y-aminobutyric acid
• document W02020044140 describes a synergistic pharmaceutical combination containing tramadol hydrochloride and pregabalin in a w/w ratio of between 1:1.5 and 1:2.5 and pharmaceutically acceptable excipients, said synergistic combination having an oral and parenteral pharmaceutical form.
• the present invention also relates to methods for treating neuropathic pain, where said neuropathic pain can be central or peripheral, among others, and to the synergistic pharmaceutical combination for use in the treatment of neuropathic pain.
• the European patent EP2343055 points out the problems of pregabalin formulation due to the presence of external factors such as humidity, which is resolved by adding high amounts of colloidal silicon dioxide, where the preferred mode of formulation of the patent is in capsules, due to the problem represented by the large number of stages involved in a formulation in tablets.
• this patent does not describe or indicate the formulation of a second drug such as tramadol and how to solve the problem of dosing a high concentration of drugs due to the limited size of the capsules, where also the dissolution, bioavailability and stability are not affected. .
• Patent document WO2008128775 claims a composition free of saccharides, lactose and does not comprise more amino acids. Same as it is formulated in the presence of water. It does not mention a special coating system, so different problems can occur during its storage, due to the lack of protection from external factors, such as light, temperature, humidity, among others, which can impact its release.
• Patent application AU2017300185 claims the extended release pregabalin composition, with a special coating system.
• Mexican patent MX276428 also mentions the addition of a coating or gelling component that can delay drug release.
• publication W02006078811 seeks to protect a coating system of three complements that provide prolonged release. The patents described above use different coating systems that impact drug release, but do not resolve the effect on the organoleptic properties of the drug, which affect its stability, dissolution and bioavailability.
• the state of the art also does not solve the problem of combining both drugs for the treatment and control of pain that, in addition to maintaining low doses, achieve a synergistic effect, improving bioavailability, dissolution, stability and at the same time a decrease in side effects. once administered to the patient.
• the lack of solutions and alternatives to the above causes the therapeutic effect to take longer to occur or a higher dose is required.
• the present invention relates to stable, immediate-release combination pharmaceutical compositions with a synergistic effect and that maintain dissolution and bioavailability, in the field of pain treatment and control.
• the present invention relates to pharmaceutical compositions comprising tramadol and pregabalin, or a pharmaceutically acceptable salt thereof, for the treatment of pain; preferably neuropathic pain; and more preferably, acute neuropathic pain;
• pain preferably neuropathic pain; and more preferably, acute neuropathic pain;
• it has improved stability, maintaining the dissolution and bioavailability of the composition to be administered.
• One embodiment of the invention comprises a composition in a single dose of tramadol hydrochloride in a concentration of 50 to 150 mg and pregabalin of 50 to 150 mg, preferably 50-100 mg and 75-150 mg, respectively.
• the composition is in the form of a tablet, tablet, caplet, granules, tablets, pills. Preferably, it is in tablet and/or tablet form.
• a more preferred pharmaceutical form is the tablet, optionally in the form of a caplet with a groove in its design.
• object of the present invention are the excipients that make up the composition that provide it with essential characteristics that improve the pharmacokinetic profile, bioavailability, stability and dissolution.
• Another modality of the invention comprises the manufacturing process of the composition that manages to overcome the technological complexity that lies in having both drugs sensitive to humidity and light in a dispensing medium in which their absorption is not affected, by means of a process that incorporates water as a solvent, because contact with the surface of the tablet is minimal, in addition, the composition has a light protection coating, so the release of both drugs is not affected.
• Figure 1 Pregabalin dissolved; comparison of dissolution profiles of reference drug [tramadol hydrochloride 50 mg/pregabalin 150 mg] and test drug [tramadol hydrochloride 50 mg/pregabalin 75 mg]; both lots of Laboratorios Silanes S.A. of C.V.
• the maximum difference between the dissolved percentages of the drug is less than or equal to 2.0% in the sampling times.
• Figure 2 Dissolved Tramadol; comparison of dissolution profiles of reference drug [tramadol hydrochloride 50 mg/pregabalin 150 mg] and test drug [tramadol hydrochloride 50 mg/pregabalin 75 mg]; both lots from Laboratorios Silanes SA de CV DETAILED DESCRIPTION OF THE INVENTION Definitions
• Pharmaceutically acceptable salt refers to salts that retain the biological efficacy and properties of the given compound, and that are not biologically or otherwise undesirable (P. Heinrich Stahl and Camille G. Wermuth (Eds.) Pharmaceutical Salts Properties, Selection, and Use (International Union of Pure and Applied Chemistry), Wiley - VCH, 2nd Revised Edition (May 16, 2011)).
• Pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amine salts.
• Suitable amines include, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine , ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
• Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
• Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
• pregabalin salts described in patent document W02009080365A1 "Pregabalin salts", where two salts derived from sulfuric acid are synthesized: pregabalin besylate and tosylate, assuming that the acid anion is not toxic to humans.
• Other salts prepared were pregabalin hydrochloride (WO 2005/041927) and pregabalin mandelate (WO 96/40617).
• Pharmaceutical Compositions may include any pharmaceutically acceptable form of pregabalin and/or tramadol, including their pharmaceutically acceptable complexes, salts, solvates, hydrates and polymorphs.
• Neuropathic pain according to the International Association for the Study of Pain, neuropathic pain is pain that is a direct consequence of an injury or disease of the somatosensory system. And this type of pain is present in various neuropathies, polyneuropathies, post-therapeutic neuralgia, other common central pain syndromes, eg spinal cord injury, spinal cord tumor, syringomyelia, cancer associated neuropathic pain.
• Excipient is the ingredient that is part of this pharmaceutical composition, among them are diluents, disintegrants, lubricants, coating systems, absorbents, among others.
• the present invention relates to stable, immediate-release pharmaceutical compositions with a synergistic effect and improved stability, maintaining dissolution and bioavailability, of an opioid analgesic and an antiepileptic/analgesic, which can be administered as a therapeutic agent to treat pain.
• the pain may be neuropathic pain, and more preferably, acute neuropathic pain.
• the opioid analgesic used is tramadol or a pharmaceutically acceptable salt thereof, for example; its hydrochloride salt and the antiepileptic/analgesic is pregabalin or a pharmaceutically acceptable salt thereof.
• tramadol and pregabalin suggests an antinociceptive effect in animal models and a decrease in adverse events of tramadol, such as seizures. (2012, Fariborz; 2015, Tewari).
• the combination of these drugs offers the possibility of efficient analgesia with a decrease in adverse events reported with monodrugs due to the reduction in the doses of one or both compounds (2017, Suthakaran).
• the combination of tramadol and pregabalin represents a set of important technological challenges due to the physicochemical properties of the drugs, the adequate selection of excipients and the manufacturing conditions play, in the development of pharmaceutical compositions, a very important role in relation to drug release and the rate of absorption in the body.
• the composition manages to overcome the technological complexity that lies in having both drugs sensitive to humidity and light in a dispensing medium in which their absorption is not affected through a process that incorporates water as a solvent, because , contact with the surface of the tablet is minimal, in addition the composition has a light protection coating, therefore, the release of both drugs is not affected.
• the present invention comprises the combination of tramadol and pregabalin or a pharmaceutically acceptable salt thereof in doses of 50 to 150 mg of tramadol and 50 to 150 mg of pregabalin; preferably, in low doses, from 50 to 100 mg of tramadol or any of its pharmaceutically acceptable salts and pregabalin or any of its pharmaceutically acceptable salts in concentrations of 75 to 150 mg, with at least one pharmaceutically acceptable excipient.
• the solid pharmaceutical composition can be found as a tablet, monolayer tablet, granules, caplet, lozenges or pills. Preferably, it is in tablet and/or tablet form.
• the most preferred pharmaceutical form of the invention is in “tablets” due to its dose accuracy, it is also the pharmaceutical form with the best acceptance due to its easy administration, making it possible to dose a high concentration of drugs, unlike capsules. In the case of tablets, it is possible to reduce the volume of the powders and thus facilitate their handling and administration.
• a preferred dosage form of the invention is the caplet-shaped tablet with a groove in its design.
• a more preferred pharmaceutical form is the biconvex tablet.
• pharmaceutically acceptable diluents include, but are not limited to cellulose derivatives, such as microcrystalline cellulose PH102, phosphate derivatives such as dibasic calcium phosphate, starch derivatives such as pregelatinized starch and corn starch, as well as mannitol, xylitol, maltitol, lactitol, sorbitol, sucrose or a combination thereof.
• the preferred diluent for the present invention is microcrystalline cellulose PH102.
• the diluent is preferably present in a concentration of 5 to 90% by weight.
• disintegrants include, but are not limited to, croscarmellose, cellulose derivatives such as hydroxypropylcellulose, carboxymethylcellulose, microcrystalline cellulose; povidone derivatives such as crospovidone; starch derivatives such as pregelatinized starch, sodium starch glycolate and corn starch.
• the disintegrant can be present in an amount ranging from 0.5 to 15% by weight, preferably between 0.5 to 3% by weight.
• the preferred disintegrant for the present formulation is croscarmellose sodium.
• Examples of pharmaceutically acceptable lubricants include, but are not limited to, magnesium stearate, zinc stearate, calcium stearate, stearic acid, monostearate, stearyl fumarate; talc and sulfated derivatives such as magnesium lauryl sulfate.
• the lubricant can be present in an amount ranging from 0.25 to 10%; more preferably 0.8% to 1% by weight.
• the preferred lubricant for the composition of the present invention is magnesium stearate.
• composition process which manages to overcome the technological complexity that lies in combining both drugs - which are sensitive to humidity and light - in a dispensing medium in which the absorption of these drugs is not affected. , through a process that incorporates water as a solvent, because contact with the surface of the tablet is minimal; In addition, the composition has a light protection coating, so the release of both drugs is not affected, but at the same time stability is improved.
• Tramadol and pregabalin are known to be drugs that are sensitive to light and humidity in the environment, which is why, to date, there are no drugs that can combine these two drugs in a single formulation without being affected by these factors.
• the production process of the tablets was rooted in the selection of the unit operations, the order and the execution time to control the different physicochemical properties of the drugs, which consisted of the selection of the correct coating ingredient and the ideal temperatures to avoid a very prolonged contact of the water with the drugs and at the same time obtain a barrier against light.
• the coating system is preferably selected from cellulose derivatives such as: hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcelluloses; polyvinyl derivatives such as polyvinyl alcohol; polyethylene glycol, povidones in all grades K and their derivatives.
• cellulose derivatives such as: hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcelluloses; polyvinyl derivatives such as polyvinyl alcohol; polyethylene glycol, povidones in all grades K and their derivatives.
• hydropropylmethylcellulose in concentrations of 0.5 to 6% by weight, preferably concentrations of 2.5 to 3.5% by weight.
• the coating preferably does not use alcohol based carriers; preferably the vehicle is water.
• the concentration of solids in the coating systems does not exceed 19.6%, which is important, because it ensures an addition of the film to the final pharmaceutical form, in such a way that the contact of the solvent with the surface of the solid dosage form or tablet is minimal.
• composition of the present invention comprises as an absorbent for the residual water of the tablet, by way of example and not limitation: aluminum derivatives (aluminum hydroxide, aluminum oxide, aluminum phosphate), clays or earths (talapugite, bentonite, hectorite, kaolin, pectin), silica derivatives (calcium silicate, colloidal silicon dioxide, magnesium aluminum silicate), cellulose derivatives (microcrystalline cellulose, cellulose), magnesium derivatives (magnesium carbonate, magnesium silicate).
• the preferable absorbent is the amorphous form of aluminum and magnesium metasilicate in concentrations of 0.5 to 90% by weight, preferably 1 to 1.5% by weight.
• the additional advantage offered by the coating system of the present invention in the tablet pharmaceutical form, preferably caplet, is that it does not interfere or delay the dissolution process of the drugs as described in the dissolution test example.
• the pharmaceutical composition does not present a pharmacokinetic interaction when the combined formulation of tramadol with pregabalin is administered.
• the dissolution profiles of the present pharmaceutical combination represent a comparison between both concentrations to demonstrate bioexemption.
• the pharmaceutical composition of the invention is manufactured with the selection of the unit operations, the order and the execution time to control the different physicochemical properties of the drugs.
• the process consisted in the selection of the correct coating ingredient and the ideal temperatures to avoid a very prolonged contact of the water with the drugs and thus obtain a barrier against light.
• unit operations we find: sieve, mix, and compress.
• the temperature of the product is essential to achieve adherence of the film to the surface of the core; in general, temperatures of 40°C to 45°C are used for this type of hydroxypropylmethylcellulose-based system.
• the process for manufacturing the tablets (in caplet form) of the present invention which comprises tramadol and pregabalin and/or their pharmaceutically acceptable salts, is presented below in a non-limiting manner:
• a pharmaceutical composition with 50 mg of tramadol hydrochloride and 75 mg of pregabalin is prepared by adding the following excipients (Table 1):
• This solid pharmaceutical composition has a solid pharmaceutical form; including but not limited to tablets, monolayer tablets, granules, caplets, tablets or pills. Preferably, it is in tablet and/or tablet form; more preferably the pharmaceutical composition with 50 mg of Tramadol hydrochloride and pregabalin 75 mg is in the pharmaceutical form of a biconvex tablet.
• a pharmaceutical composition is prepared with 50 mg of tramadol hydrochloride and 150 mg of pregabalin by adding the following excipients (Table 2):
• This solid pharmaceutical composition has a solid pharmaceutical form; including but not limited to tablets, monolayer tablets, granules, caplets, tablets or pills. Preferably, it is in tablet and/or tablet form.
• a pharmaceutical composition is prepared with 100 mg of tramadol hydrochloride and 75 mg of pregabalin by adding the following excipients (Table 3):
• This solid pharmaceutical composition has a solid pharmaceutical form; including but not limited to tablets, monolayer tablets, granules, caplets, tablets or pills. Preferably, it is in tablet and/or tablet form.
• pregabalin 150 mg / tramadol 50 mg tablets treatment C, test drug from Laboratorios Silanes
• pregabalin 150 mg capsules treatment A, reference medicine indicated by the regulatory authority
• tramadol 50 mg capsules treatment B, reference drug indicated by the regulatory authority
• the frequency was established as a single dose after administration of a single dose of the formulations.
• the study design was a crossover, 3x6x3, prospective, longitudinal single-dose combination of pregabalin 150 mg/tramadol 50 mg administered orally versus each component administered individually, with three treatments, three periods, six sequences with an elimination (washout) period of 7 days and with a number of 30 healthy subjects under fasting conditions.
• Sampling times 18 samples were taken from each research subject at the following times: 0.00 (pre-dose), 0.16, 0.33, 0.50, 1.00, 1.50, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 10.0, 14.0 , 24.0 and 36.0 hours, in each of the three periods after the administration of the drug with single doses.
• Analytical method The analytical method for plasma quantification of pregabalin and tramadol was based on the methods published by Patel et. to the. , J. Pharm. Biomed. 2009, 49(29), 354-66; Liu et. al., Eur. J. Drug Metab. Pharma. 2009, 34(3), 185-92; Vaidya et. al., Chromatographia 2007, 66(11), 925-8; and Mandal et. al., Chromatographia 2008, 67(8), 237-43 with some modifications. Blood samples from each period were received in glass tubes with sodium citrate as anticoagulant. The sample treatment technique was by precipitation, the separation technique was by HPLC using mass spectrometry detection. The analytical method complied with the validation parameters established in NOM 177-SSA1-2013.
• the dissolution test (in vitro test) is used to determine the rate (amount/time) and extent (total amount) at which a drug is released from the dosage form; in the case of the dissolution profile, it corresponds to the quantification at different times of the dissolved drug under standardized conditions.
• the importance of the dissolution test lies in the following: a) It is a guide for the development of new formulations during the development of the product: it allows evaluating the possible interference of the excipients or the manufacturing process on the release of the drug. b) Process control and quality assurance: helps to ensure continuous product quality and its optimization after a change in manufacturing, formulation, manufacturing site and process escalation. c) Indicator of in vivo development-, it is an indicator of bioavailability, it allows to establish the correlation between in vitro parameters with bioavailability results.
• Dissolution profile tests were performed for tramadol hydrochloride / pregabalin 50/75 mg tablets and tramadol hydrochloride / pregabalin 50/150 mg tablets.
• the quantification of pregabalin in the study was performed through a method previously validated under the criteria of the Official Mexican Standard NOM-177-SSAA-2013, the method was performed by high-performance liquid chromatography coupled to a UV-visible detector at a wavelength of 210 nm, in the nominal concentration range of 16.6-99.6 mcg/mL and taking samples at 10, 15, 20, 30 and 45 min.
• the dissolution medium used consisted of a 0.06 N hydrochloric acid solution.
• the method for the quantification of tramadol hydrochloride was similarly validated under the criteria of the Official Mexican Standard NOM-177-SSAA-2013, the method was performed by high resolution liquid chromatography coupled to a UV-visible detector at a wavelength of 270 nm, in the nominal concentration range of 11.1-66.6 mcg/mL and taking samples at 10, 15, 20, 25 and 30 min.
• the dissolution medium used consisted of a 0.1 N hydrochloric acid solution.
• the coefficients of variation of the percentages of dissolved drugs were less than 20% in the first sampling time and less than 10% in the subsequent sampling times for both tramadol hydrochloride and pregabalin, in both drugs. .
• the percentage of tramadol hydrochloride and pregabalin in their respective dissolution medium for both the reference drug and the test drug was greater than 85% within the first 15 minutes, these results show that the evaluated products can be considered similar without need to calculate the similarity factor f2 as it dissolves very quickly.
• the values of the similarity factor f2 are reported, being 96.2 for tramadol hydrochloride and 85.0 for pregabalin.
• the present invention which relates to immediate release, stable, combination pharmaceutical compositions in which an opioid analgesic drug such as tramadol is combined with an antiepileptic/analgesic such as pregabalin; It is useful for the treatment and control of pain such as neuropathic pain and/or acute neuropathic pain, since the synergistic effect of drugs with low doses is maintained while the dissolution and bioavailability of the composition is maintained, without losing therapeutic effect. once administered, as demonstrated with respect to the pharmacokinetic bioavailability after having administered the composition of the present invention and the reference oral formulations.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pain & Pain Management (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Inorganic Chemistry (AREA)
• Rheumatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (1)

Publications (1)

Family

ID=81853431

Family Applications (1)

Country Status (10)

Citations (13)

Family Cites Families (3)

• 2020
  • 2020-12-04 US US18/255,244 patent/US20240000727A1/en active Pending
  • 2020-12-04 CA CA3199166A patent/CA3199166A1/en active Pending
  • 2020-12-04 JP JP2023532743A patent/JP7720911B2/ja active Active
  • 2020-12-04 EP EP20964395.6A patent/EP4230199A4/en active Pending
  • 2020-12-04 MX MX2022015331A patent/MX2022015331A/es unknown
  • 2020-12-04 KR KR1020237022683A patent/KR20230117591A/ko active Pending
  • 2020-12-04 WO PCT/MX2020/050050 patent/WO2022119430A1/es not_active Ceased
• 2023
  • 2023-05-12 DO DO2023000095A patent/DOP2023000095A/es unknown
  • 2023-07-04 CO CONC2023/0008896A patent/CO2023008896A2/es unknown
  • 2023-07-04 PE PE2023002012A patent/PE20252763A1/es unknown
  • 2023-07-04 PE PE2023002013A patent/PE20252750A1/es unknown

Patent Citations (15)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events